Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.060
Filtrar
1.
J Refract Surg ; 40(9): e583-e594, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39254239

RESUMEN

PURPOSE: To compare haze and refractive outcomes in patients undergoing combined accelerated corneal cross-linking (A-CXL) and selective wavefront-guided transepithelial photorefractive keratectomy (WG-transPRK) without mitomycin C (MMC) versus those undergoing A-CXL. METHODS: This prospective study analyzed 95 eyes (86 patients) with progressive keratoconus from October 2018 to October 2022. The first group underwent CXL combined with corneal or ocular WG-transPRK (CXL+PRK, n = 52), targeting higher order aberrations (HOAs). The second underwent CXL only (n = 43), both following the same accelerated CXL protocol without MMC on the SCHWIND Amaris laser platform (SCHWIND eye-tech-solutions). Baseline and postoperative evaluations (1, 3, 6, and 12 months) included uncorrected (UDVA) and corrected (CDVA) distance visual acuity, manifest refraction, tomography, corneal HOAs, and optical coherence tomography (OCT) scans. A patented machine learning algorithm objectively detected and quantified stromal haze on OCT scans in grayscale units. RESULTS: In both groups, anterior corneal haze reflectivity and subepithelial haze peaked at 3 months postoperatively, then progressively decreased at 6 and 12 months. Haze did not differ between groups at any time point. By 12 months, CDVA increased by 2.5 lines in the CXL+PRK group (P < .001) and by 0.7 lines in the CXL group (P = .10), and maximum keratometry decreased from 51.70 ± 5.10 to 47.90 ± 7.90 diopters (D) (CXL+PRK group) (P < .001) and from 51.20 ± 5.10 to 50.30 ± 4.60 D (CXL group) (P = .004). Corneal HOAs decreased in both groups but more in the CXL+PRK group. CONCLUSIONS: Combining CXL with WG-transPRK without MMC does not result in increased haze when compared to A-CXL alone. This combined approach achieves greater improvements in visual, topographic, and aberrometric parameters. [J Refract Surg. 2024;40(9):e583-e594.].


Asunto(s)
Colágeno , Opacidad de la Córnea , Sustancia Propia , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratocono , Láseres de Excímeros , Mitomicina , Fotoquimioterapia , Queratectomía Fotorrefractiva , Fármacos Fotosensibilizantes , Refracción Ocular , Riboflavina , Tomografía de Coherencia Óptica , Agudeza Visual , Humanos , Estudios Prospectivos , Queratectomía Fotorrefractiva/métodos , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual/fisiología , Femenino , Fármacos Fotosensibilizantes/uso terapéutico , Masculino , Mitomicina/administración & dosificación , Refracción Ocular/fisiología , Adulto , Queratocono/tratamiento farmacológico , Queratocono/fisiopatología , Queratocono/metabolismo , Riboflavina/uso terapéutico , Láseres de Excímeros/uso terapéutico , Sustancia Propia/metabolismo , Fotoquimioterapia/métodos , Opacidad de la Córnea/fisiopatología , Opacidad de la Córnea/etiología , Colágeno/metabolismo , Adulto Joven , Rayos Ultravioleta , Terapia Combinada , Reticulación Corneal
2.
Int Ophthalmol ; 44(1): 382, 2024 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-39302502

RESUMEN

PURPOSE: This study aimed to identify preoperative factors that predict visual acuity and Kmax 3 years after corneal cross-linking (CXL) in patients with keratoconus (KC), and to develop a prediction model. METHODS: We enrolled 68 patients with KC and followed up on 100 eyes that received CXL for at least 3 years. Preoperative data, including age, UDVA, CDVA, cylinder, SE, and the parameters of tomography including Kmax were collected as predictors. The primary outcomes were changes in CDVA (Delta CDVA) and Kmax (Delta Kmax) postoperatively. Univariate and multivariate linear regression were used to identify the correlation between the primary outcomes and predictors and establish prediction models. RESULTS: Both CDVA and Kmax remained stable from baseline to 3 years after CXL: from 0.25 ± 0.18 to 0.22 ± 0.20 (P = 0.308) and from 58.70 ± 9.52 D to 57.02 ± 8.83 D (P = 0.187), respectively. Multivariate analysis showed that worse preoperative CDVA (ß coefficient - 0.668, P < 0.001) and lower preoperative Kmean (ß coefficient 0.018,P < 0.001) were associated with greater improvement in CDVA after CXL. A smaller preoperative eccentricity (ß coefficient 8.896, P = 0.01) and a higher preoperative Kmean (ß coefficient - 1.264, P < 0.001) predicted a more flattening of postoperative Kmax. The prediction model for CDVA (R2 = 0.43) and Kmax (R2 = 0.37) could accurately estimate treatment outcomes. CONCLUSIONS: CXL is highly effective in halting or preventing further progression of KC. The preoperative factors CDVA and Kmean were able to predict visual acuity changes 3 years after CXL. And preoperative eccentricity and Kmean could predict Kmax changes 3 years after CXL.


Asunto(s)
Colágeno , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratocono , Fotoquimioterapia , Fármacos Fotosensibilizantes , Riboflavina , Rayos Ultravioleta , Agudeza Visual , Humanos , Queratocono/tratamiento farmacológico , Queratocono/diagnóstico , Queratocono/metabolismo , Reactivos de Enlaces Cruzados/uso terapéutico , Femenino , Masculino , Fármacos Fotosensibilizantes/uso terapéutico , Adulto , Colágeno/metabolismo , Riboflavina/uso terapéutico , Fotoquimioterapia/métodos , Adulto Joven , Estudios de Seguimiento , Estudios Retrospectivos , Resultado del Tratamiento , Adolescente , Refracción Ocular/fisiología , Córnea/patología , Córnea/diagnóstico por imagen , Factores de Tiempo , Sustancia Propia/metabolismo , Sustancia Propia/efectos de los fármacos , Reticulación Corneal
3.
Arq Bras Oftalmol ; 88(1): e20230056, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39109737

RESUMEN

PURPOSE: This study aimed to analyze variations in intraoperative corneal thickness during corneal cross-linking in patients with keratoconus and to investigate its possible correlation with presurgical maximal keratometry (Kmax) and pachymetry. METHODS: This was a prospective case series. We used a method similar to the Dresden protocol, with the application of hydroxypropyl methylcellulose 0.1% hypo-osmolar riboflavin in corneas between 330 and 400 µm after epithelium removal. Corneal thickness was measured using portable calipers before and immediately after epithelium removal, and 30 and 60 min after the procedure. RESULTS: The 30 patients in this study were followed up for one year. A statistically significant difference was observed in pachymetry values during the intraoperative period (p<0.0001) and an increase of 3.05 µm (95%C1: 0.56-5.54) for each diopter was seen after epithelium removal (p0.019). We found an average Kmax difference of -2.12 D between men and women (p0.013). One year after treatment, there was a statistically significant reduction in pachymetry (p<0.0001) and Kmax (p0.0170) values. CONCLUSIONS: A significant increase in pachymetry measurements was seen during the procedure, and most patients showed a regression in Kmax and pachymetry values one year after surgery.


Asunto(s)
Córnea , Paquimetría Corneal , Reactivos de Enlaces Cruzados , Derivados de la Hipromelosa , Queratocono , Fármacos Fotosensibilizantes , Riboflavina , Humanos , Riboflavina/uso terapéutico , Femenino , Queratocono/tratamiento farmacológico , Masculino , Paquimetría Corneal/métodos , Estudios Prospectivos , Adulto , Reactivos de Enlaces Cruzados/uso terapéutico , Adulto Joven , Córnea/diagnóstico por imagen , Córnea/patología , Córnea/cirugía , Córnea/efectos de los fármacos , Derivados de la Hipromelosa/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Adolescente , Resultado del Tratamiento , Factores de Tiempo , Periodo Intraoperatorio , Valores de Referencia , Topografía de la Córnea/métodos , Reproducibilidad de los Resultados
4.
Transl Vis Sci Technol ; 13(7): 14, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-39023444

RESUMEN

Purpose: Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) stabilizes the corneal stroma and eliminates microorganisms. Numerous PACK-CXL protocols, using different energy sources and chromophores, have been applied in preclinical studies, including live animal studies, with various experimental designs and endpoints. So far, a systematic mapping of the applied protocols and consistency across studies seems lacking but is essential to guide future research. Methods: The scoping review protocol was in line with the JBI Manual for Evidence Synthesis. Electronic databases were searched (Embase, MEDLINE, Scopus, Web of Science) to identify eligible records, followed by a two-step selection process (title and abstract screening, full text screening) for record inclusion. We extracted information on (1) different PACK-CXL protocol characteristics; (2) infectious pathogens tested; (3) study designs and experimental settings; and (4) endpoints used to determine antimicrobial and tissue stabilizing effects. The information was charted in frequency maps. Results: The searches yielded 3654 unique records, 233 of which met the inclusion criteria. With 103 heterogeneous endpoints, the researchers investigated a wide range of PACK-CXL protocols. The tested microorganisms reflected pathogens commonly associated with infectious keratitis. Bacterial solutions and infectious keratitis rabbit models were the most widely used models to study the antimicrobial effects of PACK-CXL. Conclusions: If preclinical PACK-CXL studies are to guide future translational research, further cross-disciplinary efforts are needed to establish, promote, and facilitate acceptance of common endpoints relevant to PACK-CXL. Translational Relevance: Systematic mapping of PACK-CXL protocols in preclinical studies guides future translational research.


Asunto(s)
Reactivos de Enlaces Cruzados , Queratitis , Fármacos Fotosensibilizantes , Riboflavina , Animales , Queratitis/tratamiento farmacológico , Queratitis/microbiología , Reactivos de Enlaces Cruzados/uso terapéutico , Reactivos de Enlaces Cruzados/farmacología , Reactivos de Enlaces Cruzados/química , Fármacos Fotosensibilizantes/uso terapéutico , Fármacos Fotosensibilizantes/farmacología , Riboflavina/uso terapéutico , Riboflavina/farmacología , Humanos , Fotoquimioterapia/métodos , Sustancia Propia/metabolismo , Sustancia Propia/efectos de los fármacos , Rayos Ultravioleta , Colágeno/metabolismo , Reticulación Corneal
5.
Prog Retin Eye Res ; 102: 101276, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38830532

RESUMEN

Changes in the biomechanical and biochemical properties of the human cornea play an important role in the pathogenesis of ectatic diseases. A number of conditions in primarily acquired (keratoconus or pellucid marginal degeneration) or secondarily induced (iatrogenic keratectasia after refractive laser surgeries) ectatic disorders lead to decreased biomechanical stability. Corneal collagen cross-linking (CXL) represents a technique to slow or even halt the progression of ectatic pathologies. In this procedure, riboflavin is applied in combination with ultraviolet A radiation. This interaction induces the production of reactive oxygen species, which leads to the formation of additional covalent bonds between collagen molecules and subsequent biomechanical corneal strengthening. This procedure is so far the only method that partially interferes etiopathogenetically in the treatment of ectatic diseases that slows or stops the process of corneal destabilization, otherwise leading to the need for corneal transplantation. Besides, CXL process increases markedly resistance of collagenous matrix against digesting enzymes supporting its use in the treatment of corneal ulcers. Since the discovery of this therapeutic procedure and the first laboratory experiments, which confirmed the validity of this method, and the first clinical studies that proved the effectiveness and safety of the technique, it has been spread and adopted worldwide, even with further modifications. Making use of the Bunsen-Roscoe photochemical law it was possible to shorten the duration of this procedure in accelerated CXL and thus improve the clinical workflow and patient compliance while maintaining the efficacy and safety of the procedure. The indication spectrum of CXL can be further expanded by combining it with other vision-enhancing procedures such as individualized topographically-guided excimer ablation. Complementing both techniques will allow a patient with a biomechanically stable cornea to regularize it and improve visual acuity without the need for tissue transplantation, leading to a long-term improvement in quality of life.


Asunto(s)
Colágeno , Reactivos de Enlaces Cruzados , Queratocono , Fármacos Fotosensibilizantes , Riboflavina , Rayos Ultravioleta , Humanos , Queratocono/tratamiento farmacológico , Queratocono/metabolismo , Queratocono/terapia , Riboflavina/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Reactivos de Enlaces Cruzados/uso terapéutico , Colágeno/metabolismo , Fotoquimioterapia/métodos , Córnea/metabolismo , Progresión de la Enfermedad
6.
Ophthalmology ; 131(10): 1234-1242, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-38935041

RESUMEN

PURPOSE: To review the evidence on the safety and effectiveness of epithelium-off corneal collagen cross-linking (CXL) for the treatment of progressive corneal ectasia. METHODS: A literature search of the PubMed database was most recently conducted in March 2024 with no date restrictions and limited to studies published in English. The search identified 359 citations that were reviewed in abstract form, and 43 of these were reviewed in full text. High-quality randomized clinical trials comparing epithelium-off CXL with conservative treatment in patients who have keratoconus (KCN) and post-refractive surgery ectasia were included. The panel deemed 6 articles to be of sufficient relevance for inclusion, and these were assessed for quality by the panel methodologist; 5 were rated level I, and 1 was rated level II. There were no level III studies. RESULTS: This analysis includes 6 prospective, randomized controlled trials that evaluated the use of epithelium-off CXL to treat progressive KCN (5 studies) and post-laser refractive surgery ectasia (1 study), with a mean postoperative follow-up of 2.4 years (range, 1-5 years). All studies showed a decreased progression rate in treated patients compared with controls. Improvement in the maximum keratometry (Kmax) value, corrected distance visual acuity (CDVA), and uncorrected distance visual acuity (UDVA) was observed in the treatment groups compared with control groups. A decrease in corneal thickness was observed in both groups but was greater in the CXL group. Complications were rare. CONCLUSIONS: Epithelium-off CXL is effective in reducing the progression of KCN and post-laser refractive surgery ectasia in most treated patients with an acceptable safety profile. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.


Asunto(s)
Academias e Institutos , Colágeno , Reactivos de Enlaces Cruzados , Epitelio Corneal , Queratocono , Oftalmología , Fármacos Fotosensibilizantes , Riboflavina , Rayos Ultravioleta , Agudeza Visual , Humanos , Reactivos de Enlaces Cruzados/uso terapéutico , Colágeno/metabolismo , Colágeno/uso terapéutico , Dilatación Patológica/tratamiento farmacológico , Queratocono/tratamiento farmacológico , Queratocono/fisiopatología , Queratocono/metabolismo , Riboflavina/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Agudeza Visual/fisiología , Epitelio Corneal/efectos de los fármacos , Epitelio Corneal/patología , Estados Unidos , Fotoquimioterapia/métodos , Sustancia Propia/metabolismo , Sustancia Propia/efectos de los fármacos , Topografía de la Córnea , Resultado del Tratamiento , Reticulación Corneal
7.
J Refract Surg ; 40(6): e392-e397, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38848056

RESUMEN

PURPOSE: To compare the effects of corneal allogenic intrastromal ring segment (CAIRS) implantation on topographical measurements and visual outcomes of patients with keratoconus with and without corneal cross-linking (CXL) prior to the time of implantation. METHODS: Sixty-seven eyes with corneal allograft intrastromal ring segment implantation (KeraNatural; Lions VisionGift) due to advanced keratoconus were included in the study. Thirty-seven eyes had no CXL and 30 eyes had had CXL before being referred to the authors. The changes in spherical equivalent (SE), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), steep keratometry (K1), flat keratometry (K2), mean keratometry (Kmean), maximum keratometry (Kmax), and thinnest pachymetry were retrospectively analyzed 6 months after the implantation. RESULTS: The median age was 29 years in the CXL group and 24.0 years in the non-CXL group (P > .05), respectively. All topographical and visual parameters before implantation were similar in both groups (P > .05 for all parameters). At 6 months, CDVA, K1, and Kmean showed higher improvement in the non-CXL group than the CXL group (P = .030, .018, and .039, respectively). CONCLUSIONS: CAIRS surgery has a flattening effect on both the corneas with and without CXL. The cornea with prior CXL treatment had less flattening effect due to the stiffening effect of prior CXL. [J Refract Surg. 2024;40(6):e392-e397.].


Asunto(s)
Colágeno , Sustancia Propia , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratocono , Fármacos Fotosensibilizantes , Prótesis e Implantes , Implantación de Prótesis , Refracción Ocular , Agudeza Visual , Humanos , Queratocono/fisiopatología , Queratocono/metabolismo , Queratocono/tratamiento farmacológico , Queratocono/cirugía , Sustancia Propia/metabolismo , Sustancia Propia/cirugía , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual/fisiología , Adulto , Masculino , Femenino , Fármacos Fotosensibilizantes/uso terapéutico , Estudios Retrospectivos , Adulto Joven , Refracción Ocular/fisiología , Colágeno/metabolismo , Paquimetría Corneal , Riboflavina/uso terapéutico , Fotoquimioterapia/métodos , Adolescente , Rayos Ultravioleta , Trasplante de Córnea/métodos , Persona de Mediana Edad , Reticulación Corneal
8.
Turk J Ophthalmol ; 54(3): 120-126, 2024 06 28.
Artículo en Inglés | MEDLINE | ID: mdl-38853628

RESUMEN

Objectives: To investigate the clinical efficacy and safety of the modified Cretan protocol in patients with post-laser in situ keratomileusis ectasia (PLE). Materials and Methods: In this retrospective study, 26 eyes of 16 patients with PLE were treated with the modified Cretan protocol (combined transepithelial phototherapeutic keratectomy and accelerated corneal collagen cross-linking). Visual, refractive, tomographic, and aberrometric outcomes and point spread function (PSF) were recorded preoperatively and at 6, 12, and 24 months after treatment. Results: Both uncorrected and best corrected visual acuity were stable at 24 months postoperatively compared to baseline (from 0.89±0.36 to 0.79±0.33 logarithm of the minimum angle of resolution [LogMAR] and 0.31±0.25 to 0.24±0.19 LogMAR, respectively, p>0.05 for all values). The mean K1, K2, Kmean, thinnest corneal thickness, and spherical aberration at baseline were 45.76±5.75 diopters (D), 48.62±6.17 D, 47.13±5.89 D, 433.16±56.86 µm, and -0.21±0.63 µm respectively. These values were reduced to 42.86±6.34 D, 45.92±6.74 D, 44.21±6.4 D, 391.07±54.76 µm, and -0.51±0.58 µm at 24 months postoperatively (p<0.001, p=0.002, p<0.001, p=0.001, and p=0.02, respectively). The mean spherical equivalent, manifest cylinder, Kmax, central corneal thickness, other corneal aberrations (root mean square, trefoil, coma, quatrefoil, astigmatism), and PSF remained stable (p>0.05 for all variables), while anterior and posterior elevation were significantly improved at 24 months postoperatively (p<0.001 and p=0.02, respectively). No surgical complications occurred during the 24-month follow-up. Conclusion: The modified Cretan protocol is a safe and effective treatment option for PLE patients that provides visual stabilization and significant improvement in topographic parameters during the 24-month follow-up. Further studies are needed to support our results.


Asunto(s)
Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratomileusis por Láser In Situ , Fármacos Fotosensibilizantes , Refracción Ocular , Agudeza Visual , Humanos , Estudios Retrospectivos , Queratomileusis por Láser In Situ/métodos , Queratomileusis por Láser In Situ/efectos adversos , Masculino , Femenino , Adulto , Dilatación Patológica/etiología , Refracción Ocular/fisiología , Reactivos de Enlaces Cruzados/uso terapéutico , Resultado del Tratamiento , Fármacos Fotosensibilizantes/uso terapéutico , Adulto Joven , Colágeno , Láseres de Excímeros/uso terapéutico , Estudios de Seguimiento , Riboflavina/uso terapéutico , Fotoquimioterapia/métodos , Enfermedades de la Córnea/cirugía , Enfermedades de la Córnea/etiología , Enfermedades de la Córnea/diagnóstico , Enfermedades de la Córnea/fisiopatología , Córnea/patología , Córnea/cirugía , Complicaciones Posoperatorias/diagnóstico , Miopía/cirugía , Miopía/fisiopatología , Rayos Ultravioleta
9.
AAPS PharmSciTech ; 25(5): 106, 2024 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-38724834

RESUMEN

The primary factor underlying the virulence of Candida albicans is its capacity to form biofilms, which in turn leads to recurrent complications. Over-the-counter antifungal treatments have proven ineffective in eliminating fungal biofilms and the inflammatory cytokines produced during fungal infections. Chitosan nanoparticles offer broad and versatile therapeutic potential as both antifungal agents and carriers for antifungal drugs to combat biofilm-associated Candida infections. In our study, we endeavoured to develop chitosan nanoparticles utilising chitosan and the antifungal crosslinker phytic acid targeting C. albicans. Phytic acid, known for its potent antifungal and anti-inflammatory properties, efficiently crosslinks with chitosan. The nanoparticles were synthesised using the ionic gelation technique and subjected to analyses including Fourier transform infrared spectroscopy, dynamic light scattering, and zeta potential analysis. The synthesised nanoparticles exhibited dimensions with a diameter (Dh) of 103 ± 3.9 nm, polydispersity index (PDI) of 0.33, and zeta potential (ZP) of 37 ± 2.5 mV. These nanoparticles demonstrated an antifungal effect with a minimum inhibitory concentration (MIC) of 140 ± 2.2 µg/mL, maintaining cell viability at approximately 90% of the MIC value and reducing cytokine levels. Additionally, the nanoparticles reduced ergosterol content and exhibited a 62% ± 1.2 reduction in biofilm susceptibility, as supported by colony-forming unit (CFU) and XTT assays-furthermore, treatment with nanoparticles reduced exopolysaccharide production and decreased secretion of aspartyl protease by C. albicans. Our findings suggest that the synthesised nanoparticles effectively combat Candida albicans infections. In vivo studies conducted on a mouse model of vaginal candidiasis confirmed the efficacy of the nanoparticles in combating fungal infections in vivo.


Asunto(s)
Antiinflamatorios no Esteroideos , Antifúngicos , Biopelículas , Candida albicans , Candidiasis Vulvovaginal , Quitosano , Reactivos de Enlaces Cruzados , Nanopartículas , Ácido Fítico , Biopelículas/efectos de los fármacos , Ácido Fítico/química , Ácido Fítico/farmacología , Ácido Fítico/uso terapéutico , Reactivos de Enlaces Cruzados/química , Reactivos de Enlaces Cruzados/farmacología , Reactivos de Enlaces Cruzados/uso terapéutico , Quitosano/química , Quitosano/farmacología , Quitosano/uso terapéutico , Nanopartículas/química , Nanopartículas/uso terapéutico , Antifúngicos/química , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Pruebas de Sensibilidad Microbiana , Citocinas/inmunología , Candida albicans/efectos de los fármacos , Candida albicans/patogenicidad , Femenino , Animales , Ratones , Candidiasis Vulvovaginal/tratamiento farmacológico , Candidiasis Vulvovaginal/metabolismo , Vagina/microbiología
10.
Indian J Ophthalmol ; 72(Suppl 4): S639-S644, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38767551

RESUMEN

PURPOSE: This study aimed to report the long-term results of combined topography-guided photorefractive keratectomy (PRK) and accelerated corneal collagen cross-linking (CXL) for keratoconus using the Zeiss refractive coordinated system. METHODS: A prospective interventional study was conducted in a tertiary eye care hospital in South India. Patients with mild-to-moderate progressive keratoconus and corneal pachymetry greater than 450 µm were included. They underwent customized topography-guided PRK followed by CXL. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and keratometry readings and complications were evaluated at 1, 3, 6, 12, and 24 months postoperatively. RESULTS: Thirty patients (30 eyes) were included in the study. All study parameters showed a statistically significant improvement postoperatively over baseline values. At 24 months, the mean UDVA improved from 0.8 ± 0.180 logarithm of the minimum angle of resolution (logMAR) to 0.38 ± 0.118 logMAR ( P -value <0.001) and CDVA improved from 0.467 ± 0.142 logMAR to 0.227 ± 0.078 logMAR ( P -value <0.001). The mean flat, steep, and maximum keratometry values were significantly reduced by 2.133, 3, and 4.54 diopters, respectively, at the last follow-up examination ( P -value <0.001). CONCLUSION: The combined topography-guided PRK and accelerated CXL procedure seem to be a promising treatment alternative for early keratoconus. This is the first such study on the Zeiss refractive coordinated system. However, further studies with a larger study population and longer follow-up periods are required to draw final conclusions about the benefits of this procedure in keratoconus.


Asunto(s)
Colágeno , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratocono , Fotoquimioterapia , Queratectomía Fotorrefractiva , Fármacos Fotosensibilizantes , Refracción Ocular , Riboflavina , Agudeza Visual , Humanos , Queratectomía Fotorrefractiva/métodos , Queratocono/cirugía , Queratocono/diagnóstico , Queratocono/tratamiento farmacológico , Queratocono/fisiopatología , Queratocono/metabolismo , Masculino , Estudios Prospectivos , Femenino , Fármacos Fotosensibilizantes/uso terapéutico , Colágeno/metabolismo , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual/fisiología , Adulto , Adulto Joven , Fotoquimioterapia/métodos , Riboflavina/uso terapéutico , Refracción Ocular/fisiología , Estudios de Seguimiento , Láseres de Excímeros/uso terapéutico , Rayos Ultravioleta , Cirugía Asistida por Computador/métodos , Córnea/cirugía , Córnea/patología , Adolescente , Sustancia Propia/metabolismo , Sustancia Propia/cirugía , Resultado del Tratamiento , Terapia Combinada
11.
BMJ Case Rep ; 17(5)2024 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-38772872

RESUMEN

Acanthamoeba keratitis (AK) is a rare but potentially sight-threatening complication of corneal collagen crosslinking (CXL) for keratoconus. In this report, we describe an early adolescent male who underwent routine CXL for progressive keratoconus in his left eye. Preprocedural left visual acuity (VA) was 6/9. At day 5 postprocedure, multifocal corneal infiltrates were identified. Corneal scrape, bandage contact lens cultures and herpetic and Acanthamoeba PCR were negative. In vivo, confocal microscopy (IVCM) identified Acanthamoeba cysts within the corneal stroma. Intensive amoebicidal therapy was initiated, but recovery was complicated by significant inflammation, resulting in widespread aggressive corneal vascularisation necessitating topical steroids and steroid-sparing agents. At 10 months, his left VA was 6/24. This report emphasises the importance of maintaining a high index of suspicion for AK in cases of post-CXL microbial keratitis and highlights the diagnostic value of IVCM, particularly in culture-negative and PCR-negative cases.


Asunto(s)
Queratitis por Acanthamoeba , Queratocono , Microscopía Confocal , Queratitis por Acanthamoeba/diagnóstico , Queratitis por Acanthamoeba/tratamiento farmacológico , Humanos , Masculino , Queratocono/tratamiento farmacológico , Queratocono/diagnóstico , Adolescente , Riboflavina/uso terapéutico , Colágeno , Fármacos Fotosensibilizantes/uso terapéutico , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual , Córnea/parasitología , Córnea/patología , Acanthamoeba/aislamiento & purificación , Sustancia Propia/patología , Sustancia Propia/parasitología
12.
Curr Opin Ophthalmol ; 35(4): 273-277, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38700496

RESUMEN

PURPOSE OF REVIEW: To review corneal crosslinking for keratoconus and corneal ectasia, and recent developments in the field. This study will review the mechanism of crosslinking, clinical approaches, current results, and potential future innovations. RECENT FINDINGS: Corneal crosslinking for keratoconus was first approved by U.S. FDA in 2016. Recent studies have confirmed the general long-term efficacy of the procedure in decreasing progression of keratoconus and corneal ectasia. New types of crosslinking protocols, such as transepithelial treatments, are under investigation. In addition, adjunctive procedures have been developed to improve corneal contour and visual function in these patients. SUMMARY: Crosslinking has been found to be well tolerated and effective with the goal of decreasing progression of ectatic corneal diseases, keratoconus and corneal ectasia after refractive surgery. Studies have shown its long-term efficacy. New techniques of crosslinking and adjunctive procedures may further improve treatments and results.


Asunto(s)
Colágeno , Reactivos de Enlaces Cruzados , Queratocono , Fotoquimioterapia , Fármacos Fotosensibilizantes , Riboflavina , Rayos Ultravioleta , Queratocono/tratamiento farmacológico , Humanos , Reactivos de Enlaces Cruzados/uso terapéutico , Riboflavina/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Fotoquimioterapia/métodos , Dilatación Patológica/tratamiento farmacológico , Colágeno/metabolismo , Sustancia Propia/metabolismo
13.
Curr Opin Ophthalmol ; 35(4): 315-321, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38700950

RESUMEN

PURPOSE OF REVIEW: This manuscript summarizes contemporary research from 2018 to 2023 evaluating long-term (≥2 years) outcomes of corneal crosslinking (CXL) for progressive keratoconus (KCN). RECENT FINDINGS: The standard Dresden protocol (SDP) has been utilized clinically since the early 2000 s to treat ectatic disorders, primarily progressive KCN and postrefractive ectasia. Various modifications have since been introduced including accelerated and transepithelial protocols, which are aimed at improving outcomes or reducing complications. This review summarizes data demonstrating that the SDP halts disease progression and improves various visual and topographic indices (UDVA, CDVA, Kmax, K1, K2) up to 13 years postoperatively. Accelerated and transepithelial protocols have been found to be well tolerated alternatives to SDP with similar efficacy profiles. Studies focusing on pediatric populations identified overall higher progression rates after CXL. All protocols reviewed had excellent safety outcomes in adults and children. SUMMARY: Recent studies revealed that SDP successfully stabilizes KCN long term, and a variety of newer protocols are also effective. Pediatric patients may exhibit higher progression rates after CXL. Further research is required to enhance the efficacy and ease of these protocols.


Asunto(s)
Colágeno , Reactivos de Enlaces Cruzados , Queratocono , Fotoquimioterapia , Fármacos Fotosensibilizantes , Riboflavina , Agudeza Visual , Humanos , Queratocono/tratamiento farmacológico , Queratocono/fisiopatología , Reactivos de Enlaces Cruzados/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Riboflavina/uso terapéutico , Fotoquimioterapia/métodos , Colágeno/uso terapéutico , Agudeza Visual/fisiología , Rayos Ultravioleta , Sustancia Propia/metabolismo , Sustancia Propia/efectos de los fármacos , Resultado del Tratamiento , Topografía de la Córnea
14.
Cornea ; 43(9): 1184-1197, 2024 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-38759151

RESUMEN

PURPOSE: The purpose of this review was to summarize the different surgical approaches combining photorefractive keratectomy (PRK) and corneal crosslinking (CXL), present each protocol template in a simple format, and provide an overview of the primary outcomes and adverse events. METHODS: A literature review was conducted as outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Eight different databases were searched. Papers were included if PRK was immediately followed by CXL. RESULTS: Thirty-seven papers met the inclusion criteria of a total yield of 823. The latest research into simultaneous PRK and CXL has been shown to not only stabilize the cornea and prevent keratoconus progression but also improve the visual acuity of the patient. Improvements in uncorrected distance visual acuity and (spectacle) corrected distance visual acuity were found to be significant when considering all protocols. There were also significant reductions in K1, K2, mean K, Kmax, sphere, cylinder, and spherical equivalent. Random-effects analysis confirmed these trends. Corrected distance visual acuity was found to improve by an average of 0.18 ± 1.49 logMAR (Cohen's D [CD] 0.12; P <0.02). There was also a significant reduction of 2.57 ± 0.45 D (CD 5.74; P <0.001) in Kmax. Cylinder and spherical equivalent were also reduced by 1.36 ± 0.26 D (CD 5.25; P <0.001) and 2.61 ± 0.38 D (CD 6.73; P <0.001), respectively. CONCLUSIONS: Combining the 2 procedures appears to be of net benefit, showing stabilization and improvement of ectatic disease, while also providing modest gains in visual acuity. Since customized PRK and CXL approaches appear superior, a combination of these would likely be best for patients.


Asunto(s)
Colágeno , Reactivos de Enlaces Cruzados , Queratocono , Fotoquimioterapia , Queratectomía Fotorrefractiva , Fármacos Fotosensibilizantes , Riboflavina , Rayos Ultravioleta , Agudeza Visual , Queratectomía Fotorrefractiva/métodos , Humanos , Reactivos de Enlaces Cruzados/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Colágeno/metabolismo , Agudeza Visual/fisiología , Queratocono/tratamiento farmacológico , Queratocono/cirugía , Queratocono/fisiopatología , Queratocono/metabolismo , Riboflavina/uso terapéutico , Fotoquimioterapia/métodos , Láseres de Excímeros/uso terapéutico , Sustancia Propia/metabolismo , Sustancia Propia/efectos de los fármacos , Sustancia Propia/cirugía , Terapia Combinada , Refracción Ocular/fisiología , Protocolos Clínicos
16.
Eye (Lond) ; 38(13): 2522-2529, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38609652

RESUMEN

OBJECTIVES: To evaluate the 10-year visual, refractive, and tomographic outcomes of epithelium-off accelerated corneal collagen cross-linking (ACCL) in paediatric patients with progressive keratoconus (KC) and to compare the stages in terms of re-progression. METHODS: Patients under 18 years of age with progressive KC who underwent ACCL between 2010 and 2012 and completed at least 10 years of follow-up were included in this retrospective study. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refractive errors, and corneal tomography parameters were evaluated preoperatively and at 1, 5, and 10 years postoperatively. The effect of stage and age on re-progression was analysed. RESULTS: The study included 175 eyes of 97 patients (mean age: 14.46 ± 2.17 years). Improvement in UDVA and CDVA was observed in all postoperative periods compared to the preoperative period (each p-value < 0.05). The increase in spherical equivalent (SE), flattening of keratometry values, and decrease in thinnest corneal thickness (TCT) were statistically significant in the tenth year compared to preoperatively (each p-value < 0.05). Re-progression was observed in 16 eyes (9.14%). Haze was observed in 13 eyes (7.43%), 4 of which were permanent. Deep anterior lamellar keratoplasty was performed in 3 eyes (1.7%) and a second ACCL in 3 eyes (1.7%). CONCLUSIONS: ACCL is an effective and safe long-term strategy to prevent progression of KC in paediatric patients. In the light of this study with a 10-year follow-up re-progression rate of 9.14%, long-term follow-up of patients after ACCL for possible re-progression and the need for re-CCL or keratoplasty may be recommended.


Asunto(s)
Colágeno , Sustancia Propia , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Progresión de la Enfermedad , Queratocono , Fotoquimioterapia , Fármacos Fotosensibilizantes , Refracción Ocular , Riboflavina , Rayos Ultravioleta , Agudeza Visual , Humanos , Queratocono/tratamiento farmacológico , Queratocono/fisiopatología , Queratocono/metabolismo , Femenino , Masculino , Adolescente , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual/fisiología , Estudios Retrospectivos , Colágeno/metabolismo , Estudios de Seguimiento , Fármacos Fotosensibilizantes/uso terapéutico , Riboflavina/uso terapéutico , Niño , Refracción Ocular/fisiología , Fotoquimioterapia/métodos , Sustancia Propia/metabolismo , Córnea/patología
17.
Eur J Ophthalmol ; 34(4): 967-972, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38623696

RESUMEN

PURPOSE: To report the first case of Rhizopus sp keratitis in a 15-year-old male patient who had undergone a conventional Epi-off CXL procedure for progressive keratoconus. METHODS: A 15-year-old male studying at school presented with defective vision in both eyes recently. He was diagnosed with progressive keratoconus in the right eye more than left eye. After the conventional CXL procedure, the patient developed corneal ulcer on third postoperative day. RESULTS: The microbiological diagnosis of both BCL and ulcer revealed Rhizopus sp. The patient responded to topical antifungals, and the ulcer entirely healed with a large central scar. CONCLUSION: Rhizopus keratitis is rare in a healthy individual. Ours is the first case report of Rhizopus keratitis in patient undergone CXL.


Asunto(s)
Reactivos de Enlaces Cruzados , Infecciones Fúngicas del Ojo , Queratocono , Fármacos Fotosensibilizantes , Rhizopus , Riboflavina , Humanos , Masculino , Queratocono/tratamiento farmacológico , Queratocono/diagnóstico , Adolescente , Fármacos Fotosensibilizantes/uso terapéutico , Rhizopus/aislamiento & purificación , Riboflavina/uso terapéutico , Infecciones Fúngicas del Ojo/microbiología , Infecciones Fúngicas del Ojo/tratamiento farmacológico , Infecciones Fúngicas del Ojo/diagnóstico , Reactivos de Enlaces Cruzados/uso terapéutico , Fotoquimioterapia , Mucormicosis/tratamiento farmacológico , Mucormicosis/diagnóstico , Mucormicosis/microbiología , Complicaciones Posoperatorias/tratamiento farmacológico , Rayos Ultravioleta , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/tratamiento farmacológico , Úlcera de la Córnea/diagnóstico , Antifúngicos/uso terapéutico , Sustancia Propia/metabolismo , Sustancia Propia/microbiología , Agudeza Visual , Topografía de la Córnea , Queratitis/microbiología , Queratitis/tratamiento farmacológico , Queratitis/diagnóstico
18.
Oral Health Prev Dent ; 22: 171-180, 2024 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-38687029

RESUMEN

PURPOSE: To investigate the microbiological outcomes obtained with either subgingival debridement (SD) in conjunction with a gel containing sodium hypochlorite and amino acids followed by subsequent application of a cross-linked hyaluronic acid gel (xHyA) gel, or with SD alone. MATERIALS AND METHODS: Forty-eight patients diagnosed with stages II-III (grades A/B) generalised periodontitis were randomly treated with either SD (control) or SD plus adjunctive sodium hypochlorite/amino acids and xHyA gel (test). Subgingival plaque samples were collected from the deepest site per quadrant in each patient at baseline and after 3 and 6 months. Pooled sample analysis was performed using a multiplex polymerase chain reaction (PCR)-based method for the identification of detection frequencies and changes in numbers of the following bacteria: Aggregatibacter actinomycetemcomitans (A.a), Porphyromonas gingivalis (P.g), Tannerella forsythia (T.f), Treponema denticola (T.d), and Prevotella intermedia (P.i). RESULTS: In terms of detection frequency, in the test group, statistically significant reductions were found for P.g, T.f, T.d and P.i (p < 0.05) after 6 months. In the control group, the detection frequencies of all investigated bacterial species at 6 months were comparable to the baseline values (p > 0.05). The comparison of the test and control groups revealed statistically significant differences in detection frequency for P.g (p = 0.034), T.d (p < 0.01) and P.i (p = 0.02) after 6 months, favouring the test group. Regarding reduction in detection frequency scores, at 6 months, statistically significant differences in favour of the test group were observed for all investigated bacterial species: A.a (p = 0.028), P.g (p = 0.028), T.f (p = 0.004), T.d (p <0.001), and P.i (p = 0.003). CONCLUSIONS: The present microbiological results, which are related to short-term outcomes up to 6 months post-treatment, support the adjunctive subgingival application of sodium hypochlorite/amino acids and xHyA to subgingival debridement in the treatment of periodontitis.


Asunto(s)
Aggregatibacter actinomycetemcomitans , Aminoácidos , Placa Dental , Ácido Hialurónico , Porphyromonas gingivalis , Prevotella intermedia , Hipoclorito de Sodio , Tannerella forsythia , Treponema denticola , Humanos , Ácido Hialurónico/uso terapéutico , Hipoclorito de Sodio/uso terapéutico , Aggregatibacter actinomycetemcomitans/efectos de los fármacos , Aggregatibacter actinomycetemcomitans/aislamiento & purificación , Porphyromonas gingivalis/efectos de los fármacos , Femenino , Persona de Mediana Edad , Masculino , Prevotella intermedia/efectos de los fármacos , Tannerella forsythia/efectos de los fármacos , Treponema denticola/efectos de los fármacos , Adulto , Placa Dental/microbiología , Aminoácidos/uso terapéutico , Desbridamiento Periodontal/métodos , Carga Bacteriana/efectos de los fármacos , Geles , Terapia Combinada , Estudios de Seguimiento , Reactivos de Enlaces Cruzados/uso terapéutico , Bolsa Periodontal/microbiología , Bolsa Periodontal/terapia , Periodontitis/microbiología , Periodontitis/terapia , Periodontitis/tratamiento farmacológico
19.
Indian J Ophthalmol ; 72(5): 712-717, 2024 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-38648433

RESUMEN

PURPOSE: To compare the changes encountered in corneal biomechanics and aberration profile following accelerated corneal collagen cross-linking (CXL) using hypo-osmolar and iso-osmolar riboflavin in corneal thicknesses of <400 and >400 microns, respectively. METHODS: This is a prospective, interventional, comparative study involving 100 eyes of 75 patients with progressive keratoconus. Eyes were divided into two groups based on corneal thickness: group 1 included eyes with a corneal thickness of <400 microns who underwent hypo-osmolar CXL, and group 2 included eyes with a corneal thickness of >400 microns who underwent iso-osmolar CXL. Corneal biomechanical and aberration profiles were evaluated and compared between groups. RESULTS: In group 1, all higher-order aberrations (HOA) except secondary astigmatism significantly decreased from baseline; however, in group 2, only coma and trefoil decreased. The corneal resistance factor and corneal hysteresis significantly improved in both groups, which was significantly greater in group 2 than in group 1. The change in inverse radius, deformation amplitude, and tomographic biomechanical index was significantly improved in group 2 as compared to group 1. CONCLUSION: Improvement in corrected distance visual acuity and decrease in HOA were significantly better in the hypo-osmolar CXL group; however, the improvement in biomechanical strength of the cornea was significantly better in the iso-osmolar group.


Asunto(s)
Colágeno , Córnea , Topografía de la Córnea , Reactivos de Enlaces Cruzados , Queratocono , Fármacos Fotosensibilizantes , Riboflavina , Rayos Ultravioleta , Agudeza Visual , Adolescente , Adulto , Femenino , Humanos , Masculino , Adulto Joven , Fenómenos Biomecánicos , Colágeno/metabolismo , Córnea/diagnóstico por imagen , Córnea/fisiopatología , Córnea/efectos de los fármacos , Sustancia Propia/metabolismo , Sustancia Propia/efectos de los fármacos , Aberración de Frente de Onda Corneal/fisiopatología , Reactivos de Enlaces Cruzados/uso terapéutico , Estudios de Seguimiento , Queratocono/tratamiento farmacológico , Queratocono/fisiopatología , Queratocono/diagnóstico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Estudios Prospectivos , Refracción Ocular/fisiología , Riboflavina/uso terapéutico , Agudeza Visual/fisiología , Niño
20.
Eur J Ophthalmol ; 34(4): 973-979, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38632934

RESUMEN

PURPOSE: To establish new criteria for the progression of keratoconus, taking into account a Pentacam HR (high resolution) tomographers repeatability limit. METHODS: This is a retrospective observational study, including 224 eyes in 154 patients diagnosed with keratoconus and patients treated with crosslinking, with a follow-up of at least one year, in which the new progression score of the Cruces University Hospital for keratoconus progression was analyzed. This score takes into account: maximum keratometry, thinnest corneal thickness, maximum posterior elevation, vertical coma and RMS of high order aberrations, all based on the tomographer repeatability limit. The effectiveness or not of crosslinking was determined. RESULTS: The Receiver Operating Characteristics (ROC) curves obtained in our validation met the criteria by being far from the reference diagonal. Moreover, young patients are more likely to have keratoconus that progresses, and the percentage of patients that showed progression was 14.3% of the eyes studied, with the most advanced keratoconus showing the least progression. Taking into account the new progression score of the Cruces Hospital, we would have indicated crosslinking in 2 eyes only and we observed that none progressed one year after treatment. CONCLUSIONS: The the new progression score of the Cruces University Hospital is a method based on the real repeatability limit for keratoconic eyes. Moreover, it is easy to interpret and can be implemented with Pentacam software. It provides a numerical value that evaluates both the anterior and posterior surfaces of the cornea and corneal aberrations in the evolution of keratoconus.


Asunto(s)
Córnea , Topografía de la Córnea , Progresión de la Enfermedad , Queratocono , Curva ROC , Humanos , Queratocono/diagnóstico , Queratocono/fisiopatología , Estudios Retrospectivos , Femenino , Masculino , Adulto , Topografía de la Córnea/métodos , Adulto Joven , Córnea/patología , Córnea/diagnóstico por imagen , Estudios de Seguimiento , Reactivos de Enlaces Cruzados/uso terapéutico , Agudeza Visual/fisiología , Adolescente , Fármacos Fotosensibilizantes/uso terapéutico , Riboflavina/uso terapéutico , Colágeno/metabolismo , Fotoquimioterapia/métodos , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA